CFO4Life Group LLC Boosts Stake in Cencora, Inc. (NYSE:COR)

CFO4Life Group LLC lifted its position in Cencora, Inc. (NYSE:COR) by 7.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,293 shares of the company’s stock after purchasing an additional 87 shares during the quarter. CFO4Life Group LLC’s holdings in Cencora were worth $291,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of COR. Swedbank AB raised its position in Cencora by 2.3% during the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock valued at $313,863,000 after purchasing an additional 31,104 shares during the last quarter. CWA Asset Management Group LLC purchased a new stake in Cencora during the 3rd quarter valued at $285,000. United Bank boosted its stake in Cencora by 4.2% during the 3rd quarter. United Bank now owns 5,601 shares of the company’s stock valued at $1,261,000 after purchasing an additional 225 shares during the last quarter. Assetmark Inc. boosted its stake in Cencora by 33.8% during the 3rd quarter. Assetmark Inc. now owns 2,536 shares of the company’s stock valued at $571,000 after purchasing an additional 641 shares during the last quarter. Finally, Ashton Thomas Securities LLC bought a new position in shares of Cencora during the 3rd quarter valued at $41,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Trading Down 2.6 %

Shares of COR stock opened at $253.88 on Thursday. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The firm has a market cap of $49.23 billion, a PE ratio of 36.11, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The company has a 50-day moving average of $246.39 and a two-hundred day moving average of $238.81. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $263.70.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.87%. Cencora’s payout ratio is currently 31.29%.

Insider Activity

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the sale, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. This represents a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 13,648 shares of company stock valued at $3,382,462 in the last ninety days. 10.80% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

COR has been the topic of a number of recent research reports. StockNews.com raised Cencora from a “hold” rating to a “buy” rating in a report on Wednesday. Evercore ISI raised their price target on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. JPMorgan Chase & Co. upped their price objective on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Wells Fargo & Company lifted their price objective on shares of Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 29th. Finally, Mizuho initiated coverage on shares of Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective for the company. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and an average price target of $277.90.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.